Unicycive Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share of common and preferred stock (in thousands, except share and per share data):

	Year Ended December 31,			Year Ended December 31,
	2023			2024
Numerator:
Net loss	$	(30,544	)	$	(36,729	)
Less: Deemed dividends on Series A-1 Preferred Stock		(867	)
Less: Dividends on Series B-1 Preferred Stock		-			(1,095	)
Net loss attributable to common shares, basic and diluted		(31,411	)		(37,824	)

Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted		24,539,309			66,985,129
Net loss per share attributable to common stockholders, basic and diluted	$	(1.28	)	$	(0.56	)

Schedule of Outstanding Shares Potentially Dilutive Securities

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

	Year Ended December 31,		Year Ended December 31,
	2023		2024

Options to purchase common stock		10,302,086		13,671,140
Warrants to purchase common stock		4,784,193		4,784,193
Warrants to purchase convertible preferred stock		160,958,167		160,958,167
Total		6,126,863		179,413,500